These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1524908)

  • 21. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas.
    Bajetta E; Buzzoni R; Viviani S; Villani F; Piotti P; Gasparini G; Bonadonna G
    Cancer Treat Rep; 1985 Sep; 69(9):965-9. PubMed ID: 3839714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
    Takasugi BJ; Jones SE; Robertone AB
    Cancer Treat Rep; 1984 Nov; 68(11):1399-401. PubMed ID: 6498855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combination chemotherapy of advanced Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Mizunuma N; Ogawa M; Kuraishi Y; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Itami S
    Rinsho Ketsueki; 1991 Nov; 32(11):1410-5. PubMed ID: 1758048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of malignant lymphoma with single administration of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
    Oguro M; Takagi T
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):508-15. PubMed ID: 6764108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.
    Silver RT; Case DC; Wheeler RH; Miller TP; Stein RS; Stuart JJ; Peterson BA; Rivkin SE; Golomb HM; Costanzi
    J Clin Oncol; 1991 May; 9(5):754-61. PubMed ID: 2016617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [High dose cytosin arabinoside induced sinus bradycardia in a Hodgkin's lymphoma patient].
    Teke HÜ; Karagülle M; Akay OM
    Anadolu Kardiyol Derg; 2013 Sep; 13(6):618-9. PubMed ID: 24064095
    [No Abstract]   [Full Text] [Related]  

  • 28. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
    Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
    Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
    O'Donnell MR; Forman SJ; Levine AM; Territo M; Farbstein MJ; Fahey JL; Gill P; Lazar G; Nademanee A; Neely S
    Cancer Treat Rep; 1987 Feb; 71(2):187-9. PubMed ID: 3802114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
    Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study.
    Weick JK; Stephens RL; Baker LH; Jones SE
    Cancer Treat Rep; 1983 Sep; 67(9):823-5. PubMed ID: 6883359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study.
    Miller TP; Cowan JD; Neilan BA; Jones SE
    Cancer Chemother Pharmacol; 1986; 16(1):67-9. PubMed ID: 3940222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma.
    Shipp MA; Takvorian RC; Canellos GP
    Am J Med; 1984 Nov; 77(5):845-50. PubMed ID: 6496539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
    Leuk Lymphoma; 2006 Oct; 47(10):2155-62. PubMed ID: 17071490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB; Myers S; Devine S; Larson RA; Williams SF; Park CL; O'Toole K; Chandler C; Topper RL
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
    Coltman CA; McDaniel TM; Balcerzak SP; Morrison FS; Von Hoff DD
    Invest New Drugs; 1983; 1(1):65-70. PubMed ID: 6678857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.